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Abstract
Unraveling the normal physiologic role of b-amyloid is likely crucial to understanding the pathogenesis of Alzheimer’s
disease. However, progress on this question is currently limited by the high background of many ELISAs for murine b-
amyloid. Here, we examine the background signal of several murine b-amyloid ELISAs, and conclude that the majority of the
background is from non-APP derived proteins. Most importantly, we identify ELISAs that eliminate this background signal.
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Introduction
The Amyloid Hypothesis of Alzheimer’s disease states that the
accumulation of high levels of cerebral b-amyloid protein is a
central event in this illness [1]. This hypothesis has subsequently
fueled a massive research effort into understanding the physiology
of b-amyloid protein. Although b-amyloid may reach high
(nanomolar) concentrations in Alzheimer’s disease [2], b-amyloid
is also produced in the brain throughout life, and the normal in vivo
concentration in the rodent brain has been estimated to be in the
picomolar range [3,4]. Understanding how b-amyloid is normally
regulated may help us understand how it accumulates to high
levels in Alzheimer’s disease, and this realization has inspired
investigation into the normal physiologic function of b-amyloid
[4,5,6,7,8]. In addition, others have recently started using wild-
type rodents to study the function of c-secretase inhibitors [9,10].
In all of these cases, studying b-amyloid in wild-type animals
requires a reliable method of measuring low, picomolar concen-
trations of endogenous cerebral b-amyloid. However, it has been
noted by several groups that ELISAs that use common b-amyloid
antibodies (such as 4G8 and Signet 9153) give a very high
background reading with wild-type rodent brain, presumably due
to non-specific binding of various rodent brain proteins with these
antibodies [10,11,12]. This has prompted some authors to claim
that the ELISA method is flawed at measuring endogenous murine
b-amyloid [11,12]. To correct this flaw, a solid-phase extraction
technique has been proposed to chromatographically separate
wild-type rodent b-amyloid from the proteins in rodent brain that
lead to this non-specific binding [11,12]. However, some
investigators who wish to measure endogenous murine b-amyloid
may not have expertise with solid-phase extraction, which is a
technique that is not commonly used in the Alzheimer’s disease
scientific community. In this study, we use hippocampal tissue
from amyloid precursor protein knock-out (APP-KO) mice and
wild-type (WT) littermates to investigate this issue further. We
conclude that 1) The majority of the background signal seen in
ELISAs for murine b-amyloid is from non-APP derived proteins,




APP-KO mice [13] were bread against a B6 background; all
mice were purchased from Jackson labs. Hemizygous transgenic
(HuAPP695SWE)2576 mice expressing mutant human APP
(K670N,M671L) [14] were used as positive controls in several
experiments (these mice are from a colony that derives from a gift
from Karen Hsiao-Ashe). Unless otherwise specified, mice were
between 4 and 8 months (adults) when they were sacrificed for
tissue analysis. This study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of Columbia University (Protocol Number: AC-
AAAD9255).
ELISA
Mouse hippocampi were homogenized in 880 ml of tissue lysate
buffer (20 mM Tris-HCl (pH 7.4), 1 mM ethylenediaminetetra-
acetic acid, 1 mM ethyleneglycoltetraacetic acid, 250 mM sucrose)
supplemented with protease inhibitors (Roche). The tissue
homogenates were treated with diethanolamine to extract soluble
b-amyloid. We did not perfuse the mice with heparin before-hand,
as our goal is to compare the ability of various ELISAs to measure
b-amyloid without this requirement. Although heparin perfusion is
sometimes done to eliminate IgG from the brain, it is difficult to do
this when measuring acute changes in b-amyloid, or when
measuring b-amyloid in a hippocampal slice preparation. Thus,
we sought to determine whether there is an ELISA technique that
can measure b-amyloid in all circumstances without any
requirements for prior heparin perfusion.
We measured b-amyloid in our hippocampal homogenate using
the following ELISA kits: Covance Colorimetric BetaMarkTM
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Beta-Amyloid x-42 ELISA Kit (Catalog Number: SIG-38956),
Covance Colorimetric BetaMarkTM Beta-Amyloid x-40 ELISA
Kit, (Catalog Number: SIG-38954), Invitrogen Ab 42 Mouse
ELISA Kit (Catalog Number: KMB3441), Invitrogen Ab 40
Mouse ELISA Kit (Catalog Number: KMB3481), Wako Human/
Rat(Mouse) b-Amyloid (40) ELISA Kit (Catalog Number: 294-
62501), and Wako Human/Rat(Mouse) b-Amyloid (42) ELISA
High-Sensitive Kit (Catalog Number: 292-64501). All ELISA
assays were performed according to the manufacturer’s protocol.
In addition, ELISAs using either 6E10 or M3.2 as a capture
antibody and an HRP-conjugated 4G8 as a detection antibody
were prepared as previously described [11] (all antibodies were
purchased from Covance). Costar 96-well plates were incubated
overnight at 4uC with capture antibody (in 0.1 M sodium
bicarbonate, pH 8.2) at a dilution of 4 mg/mL. Plates were
blocked the following morning in Block Ace (AbD Serotech) and
then incubated overnight with 50 ml of brain lysate. The following
morning the plates were washed with PBST and then incubated
for 2 hours at room temperature with HRP-4G8 (Covance) at a
dilution of 1 mg/mL. Plates were then washed and read at 620 nM
wavelength 30 minutes after adding 100 ml of TMB substrate
(Covance). The signal was normalized to the protein concentration
for each sample. Between 5 and 6 mice were used in each group
when comparing WT and APP-KO tissue for a given ELISA. All
data analysis was done using Microsoft Excel; statistical signifi-
cance was calculated using a 2-tailed T-test.
Western Blot
Western blotting was performed as previously described [15].
Hippocampal tissue was homogenized in RIPA buffer (Fisher
scientific) with protease inhibitor (Roche) at 4uC, followed by
centrifugation at 2,000 rpm for 1 min. The supernatant was
electrophoresed on 4–12% Bis-Tris NuPAGE gels (Invitrogen) and
then immunoblotted on nitrocellulose membrane. All primary
antibodies were used at a 1:1,000 concentration for immunoblot-
ting. HRP-conjugated secondary antibodies were purchased from
Millipore. Although we do not quantify the bands in this paper,
the same amount of protein (30 mg) was loaded for each sample for
ease of comparison.
Results
When interpreting the signal from a b-amyloid ELISA, we
assume that any signal with APP-KO tissue is pure noise, whereas
signal from WT tissue is noise plus genuine signal from murine b-
amyloid. We first compared the ability of six commercially
available ELISAs from three different companies to distinguish
WT from APP-KO hippocampal lysate (see Methods for details
and catalog numbers). We first tried the Covance b-amyloid x-40
and x-42 ELISA kits. We found that both kits gave a strong signal
for both WT and APP-KO mice (Figure 1A). In fact, there was no
significant difference between WT and APP-KO mice for the x-40
kit (p-value = 0.3). For the x-42 kit the difference was significant (p-
value = 0.03), but there was still a strong signal generated by APP-
KO hippocampal tissue. For both of the Covance kits, the signal
generated by the APP-KO tissue was statistically different from
blank (p-value = 0.0001 for the x-40 kit; p-value = 0.015 for the x-
42 kit). We next tried the Invitrogen mouse b-amyloid 40 and b-
amyloid 42 kits. Both kits gave a substantial and statistically
significant difference between WT and APP-KO mice (Figure 1B).
However, the APP-KO signal was still statistically different from
blank in both cases (p-value = 0.002 for the b-amyloid 42 kit; p-
value = 0.0004 for the b-amyloid 40 kit). Interestingly, the total
amount of b-amyloid detected by the Invitrogen kits is significantly
less than the amount detected by the Covance kits (when
normalized by protein levels). This may be due to the fact that
the Covance kits are detecting significant amounts of other
proteins in addition to b-amyloid. Consistent with this second
possibility, the APP-KO tissue has a strong signal with the
Covance kits. Finally, we ran the same experiment with the b-
Amyloid 40 and b-Amyloid 42 High-Sensitive kits from Wako
chemicals. These kits both gave a large, statistically significant
difference between WT and APP-KO tissue (Figure 1C). In fact,
the b-Amyloid 42 High-Sensitive kit gave a signal with the APP-
KO tissue that was effectively at our blank reading (it was actually
slightly below). The Wako b-Amyloid 40 kit gave a positive
background reading with APP-KO tissue, but it was not
statistically significantly different from the blank reading (p-
value = 0.49).
How much of the background noise in the above ELISAs is
from fragments of APP other than b-amyloid and how much is
from non-APP derived proteins? Since APP-KO mice give a
robust signal with many of the above kits, we assume that a large
portion of the noise in these kits is due to proteins not derived from
APP. However, there remains the possibility that some of the
signal in WT mice is coming from APP-derived fragments other
than b-amyloid. Definitively answering this question is somewhat
tricky, as APP has multiple proteolytic fragments. In addition,
most commercially available ELISA kits do not disclose which
antibodies are used in them; this is true both for the Covance and
the Invitrogen kits that had significant background activity from
APP-KO tissue. Thus, in order to further investigate this issue, we
decided to design an ELISA that was specific for human b-
amyloid, and measure the signal from WT and APP-KO tissue
with this ELISA. This ELISA should not detect murine b-amyloid
[11]. Thus, if the signal from APP-KO and WT mice is equal in
this ELISA, then this argues that at least in this case, the noise is
coming entirely from non-APP derived proteins. To do this, we
made an ELISA using 6E10 (a human-specific b-amyloid
antibody) as the capture antibody and HRP-conjugated 4G8
(which recognizes both rodent and human b-amyloid) as the
detection antibody. As seen in Figure 1D, both APP-KO and WT
mice gave a strong signal with this ELISA, and both signals are of
comparable strength. To verify that our ELISA was working
correctly, we first successfully measured step-wise dilutions of
human synthetic b-amyloid (data not shown). As an additional
control, we then asked whether this ELISA could have detected
murine b-amyloid if the capture antibody had been for rodent b-
amyloid. To do this, we ran the exact same ELISA with APP-KO
and WT tissue, but changed the capture antibody from human-
specific 6E10 to rodent-specific M3.2; the ELISA was identical in
all other respects. This ELISA should now give a clear difference
between WT and APP-KO tissue, although there may well be
some background signal with the APP-KO tissue. As expected, this
ELISA gave a strong signal in WT tissue and a smaller, but
statistically significant signal in APP-KO tissue (Figure 1D). The
very strong signal seen with the WT tissue in the M3.2 ELISA
suggests that there is a significant contribution from proteins other
than b-amyloid. Since the APP-KO tissue only gives a small signal,
it is likely that this ELISA not only cross-reacts with other non-
APP related proteins, but also cross-reacts with other proteins
derived from APP other than b-amyloid. The M3.2 and 4G8
antibodies are known to cross-react with multiple APP fragments
[16,17]. Thus, it is reasonable to assume that other APP-related
fragments partially contribute to the WT signal in our M3.2
ELISA.
We next quantified the ‘‘signal to noise’’ ratio for each ELISA
we had run (Figure 1E), which we define as the ratio of the WT
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signal to APP-KO signal for each ELISA. Note that we give the
Wako b-Amyloid 42 High-Sensitive kit a ratio of ‘‘‘’’ because the
denominator is zero. Also note that the Invitrogen kits and the
M3.2 homemade ELISA all give a large difference between WT
and APP-KO brain tissue. However, because the APP-KO signal
is statistically significant in all of these ELISAs, the signal/noise
ratio for these ELISAs is much smaller than the Wako ELISA kits.
Finally, we ran western blots using the three antibodies from our
homemade ELISAs (M3.2, 4G8, and 6E10) on hippocampal tissue
from WT, APP-KO, and APP transgenic mice expressing human
APP (HuAPP695SWE) (Figure 2). Although antibodies may bind
proteins in a western blot that they do not bind in an ELISA [2],
we did this experiment as an additional test of antibody specificity
for b-amyloid. Surprisingly, WT and APP-KO tissue showed a
very similar band pattern for all three antibodies. 4–8 month old
APP transgenic tissue also showed a similar band pattern, although
4G8 and 6E10 detected b-amyloid when brain tissue from 28
month old transgenic mice was used. In addition, 6E10 detected
an 87 kD band in APP transgenic tissue that is probably full-length
human APP. In summary, the similar band pattern between WT
and APP-KO tissue is consistent with our general conclusion that
many b-amyloid antibodies show non-specific binding. Because we
have used APP-KO tissue in this analysis, this also supports the
conclusion that much of the non-specific binding is with proteins
that are not derived from APP.
Discussion
In conclusion, we have confirmed prior reports of non-
specificity of b-amyloid antibodies when performing ELISAs for
murine b-amyloid with rodent brain tissue [10,11,12]. By
performing our experiments with APP-KO mice, we have
demonstrated that much of the observed cross-reactivity is not
with other proteolytic fragments of APP, but with other non-APP
related proteins found in rodent brain. Most importantly, we have
shown that not all b-amyloid ELISAs show high non-specificity,
Figure 1. The amount of background signal with APP-KO tissue varies widely between different ELISAs. A) The Covance Colorimetric
BetaMarkTM Beta-Amyloid x-40 ELISA Kit (left) and x-42 Kit (right). Both kits give a signal with APP-KO tissue that is significantly above baseline. The x-
40 kit gives a signal with APP-KO tissue that is not significantly different from WT (the difference between APP-KO and WT is significant for the x-42
kit). B) The Invitrogen Ab 40 Mouse ELISA Kit (left) and Ab 42 Mouse ELISA Kit (right). Both kits give a signal with APP-KO tissue that is significantly
above baseline, but also significantly different from WT tissue. C) The Wako b-Amyloid (40) ELISA Kit (left) and b-Amyloid (42) ELISA High-Sensitive Kit
(right). Both kits give a signal with APP-KO tissue that is not statistically significant from baseline. D) Both WT and APP-KO give a similar level of
background signal with an ELISA for human b-amyloid (6E10 capture antibody – left), but show a clear difference when a rodent-specific capture
antibody is used (M3.2 antibody – right). E) ‘‘Signal to noise’’ ratio of the WT signal divided by the APP-KO signal for each ELISA. Error bars in A–D are
standard error.
doi:10.1371/journal.pone.0055647.g001
A Way to Detect Endogenous Murine b-Amyloid
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e55647
and investigators may detect endogenous murine b-amyloid in
rodent brain tissue using an ELISA without a prior solid-phase
extraction step. Finally, we want to emphasize that our findings
here pertain to the detection of endogenous murine b-amyloid. For
example, the Covance kits will have less of an issue measuring
fluctuations of human b-amyloid in transgenic animals. This is
because the huge amount of b-amyloid that is produced in
transgenic mice will be much higher than the background signal.
For example, some authors have estimated that 35 times as much
b-amyloid is being produced in transgenic mice than in wild-type
rodents [10]. Thus, the Covance kits may still be quite useful in
these kinds of experiments.
Measuring natural variations in murine endogenous b-amyloid
is important for understanding the physiology of this protein, and
the work done here will hopefully make it easier for researchers to
select the appropriate kit for their work. An interesting side issue is
whether there are significant differences in endogenous b-amyloid
levels in different strains of mice, and whether this affects the
choice of kit for different mouse strains. In our own work we have
used the Wako high-sensitive b-amyloid 42 kit on several different
strains of mice (C57B6, FVB, C57B6/129 hybrids, and C57B6/
Swiss Webster hybrids), and we have found roughly comparable
levels of b-amyloid 42. Thus, although the work in this paper was
done with C57B6 mice, we believe that the results extrapolate to
other mouse strains as well.
In table 1, we summarize the strengths and weaknesses of the six
commercially available kits tested here. In summary, the ELISAs
tested in this paper range from being rodent-specific (Invitrogen) to
Figure 2. Several b-amyloid antibodies show high non-specificity for b-amyloid by western blot. A) Western blot with the antibody M3.2
(specific for rodent b-amyloid) using hippocampal tissue from APP-KO, WT, and APP transgenic mice expressing human APP (HuAPP695SWE). All
three genotypes show a similar band pattern. B) Western blot with the antibody 6E10 (specific for human b-amyloid). All three genotypes show a
similar band pattern. However, with 6E10, the APP transgenic mouse tissue shows an additional 8 kD band (presumably a human b-amyloid dimer) as
well as a band near 87 kD (presumably full-length human APP). In addition, a 4.5 kDa band (b-amyloid) is detected when older mouse brain is used
that has high levels of b-amyloid protein. C) Western blot with 4G8. All three genotypes also showed a similar band pattern with this antibody as well.
In addition, a 4.5 kDa band (b-amyloid) is detected when older mouse brain is used that has high levels of b-amyloid protein.
doi:10.1371/journal.pone.0055647.g002
Table 1. Summary of Commercially Available Kits We Tested.
Covance Ab x-40 Covance Ab x-42 Invitrogen Ab 40 Invitrogen Ab 42 Wako Ab 40 Wako Ab 42
Species Rodent and Human Rodent and Human Rodent Rodent Rodent and Human Rodent and Human
Signal to
Noise Ratio
Poor Poor Good Good Excellent Excellent
Cost Lowest Lowest Low-Intermediate Low-Intermediate Highest Highest
doi:10.1371/journal.pone.0055647.t001
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working with both rodents and humans (Covance and Wako). The
fact that the Invitrogen kit is rodent specific gives this kit a unique
advantage over the Covance and Wako kits. Namely, the
Invitrogen kit can be used to measure the physiology of
endogenous rodent b-amyloid in transgenic mice that also express
human b-amyloid. Any experiment that examines endogenous b-
amyloid processing in transgenic mice must use this kit, as the
Wako and Covance kits will not distinguish between endogenous
and human b-amyloid. The signal-to-noise ratio ranges from poor
(Covance) to excellent (Wako). Thus, in terms of signal-to-noise
ratio, the Wako kits are the best. Finally, cost must be a
consideration when choosing an ELISA kit. The Covance kits are
cheaper than either the Invitrogen or Wako kits, so this may be a
reason to choose these kits if they fit the experiment one is trying to
do (for example, measure human b-amyloid in a transgenic
mouse).
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